

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 582 790 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
23.12.1998 Bulletin 1998/52

(51) Int Cl.⁶: **C07C 237/26**, C07D 295/15,
C07D 233/56

(21) Application number: **93107719.2**

(22) Date of filing: **12.05.1993**

(54) **Novel method of producing 7-(substituted)-9-[(substituted
glycyl)amido]-6-demethyl-6-deoxytetracyclines**

Neues Verfahren zur Herstellung von 7-(substituierten)-9-[(substituierter
Glycyl)amido]-6-demethyl-6-deoxytetracyclinen

Nouveau procédé pour la préparation de (substituées)-7[(substitué glycyl)amido]-9 déméthyl-6
déoxy-6 tétracyclines

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **13.08.1992 US 928588**

(43) Date of publication of application:
16.02.1994 Bulletin 1994/07

(73) Proprietor: **American Cyanamid Company**
Madison, New Jersey 07940-0874 (US)

(72) Inventors:
• **Sum, Phalk-Eng**
Pomona, New York (US)

• **Lee, Ving J.**
Monsey, New York 10952 (US)

(74) Representative: **Wileman, David Francis Dr.**
c/o Patent Department
Wyeth Laboratories
Huntercombe Lane South
Taplow Maidenhead Berkshire SL6 0PH (GB)

(56) References cited:
EP-A- 0 536 515 **US-A- 3 338 963**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 0 582 790 B1

Description

The invention relates to a novel method for producing [4S-(4 α phen 12 α phen)]-4-(dimethylamino)-7-(substituted)-9-[[[(substituted amino)substituted]-amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides, herein after called 7-(substituted)-9-[(substituted glycy)]amino]-6-demethyl-6-deoxytetracyclines, which are useful as antibiotic agents.

The invention also relates to making novel, straight or branched 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline intermediates, which are useful for making the novel compounds of the present invention

This invention is concerned with a novel method for producing 7-(substituted)-9-[(substituted glycy)]amino]-6-demethyl-6-deoxytetracyclines, represented by formula I:



I

wherein:

X is selected from amino, -NR¹R², or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = -NR¹R² and R¹ = hydrogen,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R¹ = methyl or ethyl,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R¹ = n-propyl,

R² = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R¹ = 1-methylethyl,

R² = n-butyl, 1-methylpropyl or 2-methylpropyl; and when R¹ = n-butyl,

R² = n-butyl, 1-methylpropyl or 2-methylpropyl; and when R¹ = 1-methylpropyl,

R² = 2-methylpropyl;


R is selected from R⁴(CH₂)_nCO-, n = 0-4,

and when n = 0,

R⁴ is selected from α -aminomethyl, α -aminoethyl, α -aminobutyl, aminoisobutyl and the enantiomers of said group;

and when n = 1-4,

R⁴ is selected from amino; monosubstituted amino group selected from straight or branched (C₁-C₆)alkyl (substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-2-ethylpropyl), cyclopropylamino, cyclobutylamino, benzylamino and phenylamino; disubstituted amino group selected from dimethylamino, diethylamino, methyl(butyl)amino, ethyl(1-methylethyl)amino, monomethylbenzylamino; a cyclic amino group selected from aziridinyl, azetidiny, pyrrolidinyl, 2-methylpyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl); (C₂-C₄)-carboxyalkylamino group selected from aminoacetic acid, α -aminopropionic acid and the enantiomers of said carboxy(C₂-C₄)alkylamino group which comprises reacting a haloacyl halide compound of the formula:




wherein when $n = 0$,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloroisobutyl;


and when $n = 1-4$,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate;

and Q is halogen selected from bromine, chlorine, fluorine and iodine with a 9-amino-7-(substituted)-6-demethyl-6-deoxytetracycline compound of the formula:



wherein X is as defined hereinabove or the pharmacologically acceptable organic and inorganic salts thereof to obtain a 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline intermediate of the formula:



wherein X, Y and n are as defined hereinabove or the organic or inorganic salts thereof and reacting the intermediate, 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salts thereof, with a nucleophile of the formula R^4H , wherein R^4 is as defined hereinabove, to obtain a 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracycline compound according to formula I or the organic and inorganic salts thereof.

This novel method is an efficient way of preparing the 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salts. The novel method permits these compounds to be prepared in two reactions. The first reaction results in the formation of a common intermediate, 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salts thereof. The second reaction permits the common intermediate to be reacted with a wide variety of amines and results in a wide spectrum of 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracyclines or the pharmacologically acceptable organic and inorganic salts thereof. The use of difficult protecting groups is eliminated, thus allowing the final products to be formed in only two reactions.

Preferred is a method for producing compounds according to the above formula I wherein:

X is selected from amino, -NR¹R², or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = -NR¹R² and R¹ = hydrogen,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R¹ = methyl or ethyl

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl;

R is selected from R⁴(CH)_nCO-, n = 0-4,

and when n = 0,

R⁴ is selected from α-amino(C₁-C₄)alkyl group selected from α-aminomethyl, α-aminoethyl,

α-aminobutyl and the enantiomers of said α-amino(C₁-C₄)alkyl group;

and when n = 1-4,

R⁴ is selected from amino; monosubstituted amino group selected from straight or branched (C₁-C₆)alkyl (substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-2-ethylpropyl), cyclopropylamino, cyclobutylamino, benzylamino and phenylamino; disubstituted amino group selected from dimethylamino, diethylamino, methyl(butyl)amino, ethyl(1-methylethyl)amino, monomethylbenzylamino; cyclic amine selected from aziridinyl, azetidyl, pyrrolidinyl, 2-methylpyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl); (C₂-C₄)carboxyalkylamino group selected from aminoacetic acid, α-aminopropionic acid and the enantiomers of said carboxy(C₂-C₄)alkylamino group; and the pharmacologically acceptable organic and inorganic salts.

Particularly preferred is a method for producing compounds according to formula I wherein: X is selected from amino, -NR¹R², or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine;

and when X = -NR¹R² and R¹ = hydrogen,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R¹ = methyl or ethyl,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

R is selected from R⁴(CH)_nCO-, n = 0-4,

and when n = 0,

R⁴ is selected from α-amino(C₁-C₄)alkyl group selected from α-aminomethyl, α-aminoethyl, α-aminobutyl and the enantiomers of said (α-amino(C₁-C₄)alkyl group; and when n = 1-4,

R⁴ is selected from amino; monosubstituted amino group selected from straight or branched (C₁-C₆)alkyl (substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-2-ethylpropyl), cyclopropylamino, cyclobutylamino and benzylamino; disubstituted amino group selected from dimethylamino, diethylamino, methyl(butyl)amino, ethyl(1-methylethyl)amino, monomethylbenzylamino; cyclic amine group selected from aziridinyl, azetidyl, pyrrolidinyl, 2-methylpyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and

4-(1,2,4-triazolyl); (C₂-C₄)carboxyalkylamino group selected from aminoacetic acid, α-aminopropionic acid and the enantiomers of said carboxy(C₂-C₄)alkylamino group; and the pharmacologically acceptable organic and inorganic salts.

Most particularly preferred is a method for producing compounds according to formula I wherein:

X is selected from amino, -NR¹R², or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = -NR¹R² and R¹ = hydrogen,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when R¹ = methyl or ethyl,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

R is selected from R⁴(CH)_nCO-, n = 0-4,

and when n = 0,

R⁴ is selected from α-amino(C₁-C₄)alkyl group selected from α-aminomethyl, α-aminoethyl, α-aminopropyl, α-aminobutyl and the enantiomers of said α-amino(C₁-C₄)alkyl group;

and when n = 1-4,

R^4 is selected from amino; monosubstituted amino group selected from straight or branched (C_1 - C_6)alkyl; (substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethyl-ethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl and 1-methyl-2-ethylpropyl), cyclopropylamino, cyclobutylamino and benzylamino; disubstituted amino group selected from dimethylamino, diethylamino, methyl(butyl)amino, ethyl(1-methylethyl)amino, monomethylbenzylamino, cyclic amine selected from aziridinyl, azetidyl, pyrrolidinyl, 2-methylpyrrolidinyl, piperidinyl, morpholinyl, imidazolyl and 1-pyrrolyl; (C_2 - C_4)carboxyalkylamino group selected from aminoacetic acid and the pharmacologically acceptable organic and inorganic salts.

Of special interest is a method for producing compounds according to formula I wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when $X = -NR^1R^2$ and when $R^1 =$ methyl or ethyl,

$R^2 =$ methyl or ethyl;

R is selected from $R^4(CH)_nCO-$, $n = 0-4$,


and when $n = 0$,

R^4 is selected from α -amino(C_1 - C_4)alkyl group selected from α -aminomethyl, α -aminoethyl, and the enantiomers of said α -amino(C_1 - C_4)alkyl group;


and when $n = 1-4$,

R^4 is selected from amino; monosubstituted amino group selected from straight or branched (C_1 - C_6)alkyl (substitution selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, n-pentyl and n-hexyl), cyclopropylamino and benzylamino; disubstituted amino group selected from dimethylamino, diethylamino, methyl(butyl)amino, cyclic amino group selected from azetidyl, pyrrolidinyl, piperidinyl, morpholinyl and 1-imidazolyl; and the pharmacologically acceptable organic and inorganic salts.

The present invention further provides a process for producing 7-(substituted)-9-[(substituted glycy)amino] - 6-demethyl-6-deoxytetracyclines of the formula:



wherein X is dimethylamino and R is selected from:




which comprises:

(a) mixing 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof with a polaraprotic solvent, an inert solvent, a base and reacting with 2-bromo-propionyl bromide for 0.5 to 5 hours at from room temperature to the reflux temperature of the reaction and recovering 9-[(2-bromo-1-oxopropyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable

(b) reacting the 9-[(2-bromo-1-oxopropyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof, in a polar-aprotic solvent, under an inert atmosphere of helium, nitrogen or argon, with dimethylamine or methylamine, for from 0.5 to 2 hours at from room temperature to the reflux temperature of the reaction and isolating the product or the pharmacologically acceptable organic and inorganic salt thereof.

10

Also included in the present invention is a method for making a novel straight or branched 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline intermediate useful for producing the above compounds of formula I. Such intermediate includes those having the formula II:



25

wherein:

30

and when R¹ = methyl or ethyl,

35

R² = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

R² = n-butyl, 1-methylpropyl or 2-methylpropyl;

R² = n-butyl, 1-methylpropyl or 2-methylpropyl;

40

R² = 2-methylpropyl;


and when $n = 0$,

45

and when $n = 1-4$,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate; and the pharmacologically acceptable organic and inorganic salt.

50



wherein Y, n and Q are as defined hereinabove

Preferred is a method for producing compounds according to the above formula II wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine and when $X = -NR^1R^2$ and $R^1 =$ hydrogen,

$R^2 =$ methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when $R^1 =$ methyl or ethyl,

$R^2 =$ methyl, ethyl, n-propyl, 1-methylethyl, n-butyl

and when $n = 0$,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl ;

and when $n = 1-4$,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate; and the pharmacologically acceptable organic and inorganic salt.

Particularly preferred is a method for producing compounds according to formula II wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when $X = -NR^1R^2$ and $R^1 =$ hydrogen,

$R^2 =$ methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when $R^1 =$ methyl or ethyl,

$R^2 =$ methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when $n = 0$,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl ;

and when $n = 1-4$,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate; and the pharmacologically acceptable organic and inorganic salt.

Most particularly preferred is a method for producing compounds according to formula II wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when $X = -NR^1R^2$ and $R^1 =$ hydrogen,

$R^2 =$ methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;

and when $R^1 =$ methyl or ethyl,

$R^2 =$ methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when $n = 0$,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl ;

and when $n = 1-4$,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate; and the pharmacologically acceptable organic and inorganic salt.

Of special interest is a method for producing compounds according to formula II wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when $X = -NR^1R^2$ and when $R^1 =$ methyl or ethyl,

$R^2 =$ methyl or ethyl;

and when $n = 0$,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl ;

and when $n = 1-4$,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate; and the pharmacologically acceptable organic and inorganic salt.

The novel method of the present invention, Scheme III, provides an easier way of preparing 7-(substituted)-9-[(substituted glycyloamino]-6-demethyl-6-deoxytetracyclines or their pharmacologically acceptable organic and inorganic salts. This novel method provides a way to prepare some of the 7-(substituted)-9-[(substituted glycyloamino]-

EP 0 582 790 B1

6-demethyl-6-deoxytetracyclines or their pharmacologically acceptable organic and inorganic salts that would be very difficult to prepare using either of the prior art methods shown in Scheme I or II.

5

10

15

20

25

30


35

40

45

50

55

Scheme I

Scheme II

5

10

15

20

25






30

35

40

45

50




55

The method shown in Scheme I is premised on a reductive N-alkylation of the 9-(glycylamino)-7-(substituted)-6-demethyl-6-deoxytetracycline. It is possible to use this method only when two identical substituents are incorporated on the nitrogen. It would be unworkable to incorporate sequentially two different substituents on the nitrogen because the reductive alkylation conditions are such that both hydrogens are substituted at the same time. Thus, using the

method of Scheme I. It would not be possible to incorporate a single substituent efficiently. In addition, the initial reaction of the (succinylloxycarbonyl)methyl carbamic acid tert-butyl ester with the appropriate 9-amino-7-(substituted)-6-demethyl-6-deoxytetracycline affords only moderate yields.

The method shown in Scheme II is premised on forming an acid chloride from a mono- or disubstituted (C_1 -(C_1 - C_6)amino substituted acyl acid and reacting the so formed acid chloride with the amine at the 9-position of the 9-amino-7-(substituted)-6-demethyl-6-deoxytetra-cycline. Typically, the acid chloride is formed by the reaction of the appropriate mono- or disubstituted-(C_1 - C_6)amine with either haloacetic acids (or esters) or their synthetic equivalents, e.g. p-toluenesulfonyloxycetic acid or methanesulfonyloxycetic acid. In the case of N-(monosubstituted)amino acids the method shown in Scheme II may be utilized only via the use of nitrogen protecting groups. However, the protecting groups must survive the acyl chloride formation reactions, but also be readily removed from the final products without detriment to the appended tetracycline nucleus. The inclusion of protecting groups in this process incurs additional steps and is operationally complex. By the method shown in Scheme II, for every new structural entity e.g. 9-[(substituted glycyloamino)-7-(substituted)-6-demethyl-6-deoxy-a minimum of 4 synthetic steps and as many as 8 synthetic steps would be required.

In contrast, the novel method of the present invention allows the formation of the final product in only two synthetic steps. According to the novel method in Scheme III, the incorporation of the monosubstituted(C_1 - C_6)amines or disubstituted(C_1 - C_6)amines onto the 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracyclines does not require the use of nitrogen protecting groups. Thus, this process allows use of structurally unique or chemically sensitive amines, e.g. amines which may decompose due to excessive acid. These precious amines could be utilized in the process with operational efficiency. Since many amines are volatile, their removal from the reaction mixture by vacuum distillation will minimize byproducts that can complicate the purification process. By inference, the amines could also be recovered for further use. Most important, a broader diversity of structural entities may be obtained with no more than 2 synthetic steps.

Scheme III


In accordance with the novel method of the present invention, Scheme III, the starting 9-amino-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt, prepared by the procedure described in U.S. Patent Application, Serial No. 771,576, filed Oct. 4, 1991, is mixed with

a) a polar-aprotic solvent such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone hereinafter called DMPU, hexamethylphosphoramide hereinafter called HMPA, 1,3-dimethyl-2-imidazolidinone, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,2-dimethoxyethane or equivalent thereof;

b) an inert solvent, such as acetonitrile, methylene chloride, tetrahydrofuran, chloroform, carbon tetrachloride, 1,2-dichloroethane, tetrachloroethane, diethyl ether, t-butyl methyl ether, isopropyl ether or equivalent thereof;

c) a base such as sodium carbonate, sodium bicarbonate, sodium acetate, potassium carbonate, potassium bicarbonate, triethylamine, cesium carbonate, lithium carbonate or bicarbonate equivalents; and

d) a straight or branched haloacyl halide of the formula:



wherein Y, n and Q are as hereinabove defined: such as bromoacetyl bromide, chloroacetyl chloride or 2-bromopropionyl bromide; the halo and halogen in the haloacyl halide can be the same or different and are selected from chlorine, bromine, iodine and fluorine;

e) for 0.5 to 5 hours at from room temperature to the reflux temperature of the reaction; to form the corresponding 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or their pharmacologically acceptable organic and inorganic salt.

To produce the 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracycline or its pharmacologically acceptable organic and inorganic salts, 9-[(haloacyl)amido]-7-(substituted)-6-demethyl-6-deoxytetracycline or their pharmacologically acceptable organic and inorganic salts, is treated, under an atmosphere of argon, nitrogen or helium, with

a) a nucleophile R^4H , wherein R^4 is as defined hereinabove, such as an amine or substituted amine for example methylamine, dimethylamine, ethylamine, n-butylamine, propylamine or n-hexylamine;

b) in a polar-aprotic solvent such as DMPU, HMPA, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,2-dimethoxyethane, tetrahydrofuran, or a polar-protic solvent such as water, methanol or equivalents thereof;

c) for from 0.5 - 2 hours at room temperature or under reflux temperature to produce the desired 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracycline, or their pharmacologically acceptable organic and inorganic salts.

In the event that inorganic and organic salt forms are desired, the 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracyclines may be obtained as inorganic and organic salts using methods known to those skilled in the art (Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, flowability, hygroscopicity and solubility. Preferably, the 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracyclines are obtained as inorganic salt such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salt such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate, alkylsulfonate or arylsulfonate. Depending on the stoichiometry of the acids used, the salt formation occurs with the C(4)-dimethylamino group (1 equivalent of acid) or with both the C(4)-dimethylamino group and the substituent at the R^4 group (2 equivalents of acid). The salts are preferred for oral and parenteral administration.

Some of the compounds of the hereinbefore described Scheme III have centers of asymmetry at the carbon bearing the R^4 substituent. The compounds may, therefore, exist in at least two (2) stereoisomeric forms. The present invention encompasses a method of producing the racemic mixture of stereoisomers as well as all stereoisomers of the compounds whether free from other stereoisomers or admixed with stereoisomers in any proportion of enantiomers. The absolute configuration of any compound may be determined by conventional X-ray crystallography. The stereochemistry of the centers on the tetracycline unit (i.e. C-4, C-4a, C-5a and C-12a) remain intact throughout the reaction sequences.

This invention will be described in greater detail with the following non limiting examples.

Comparative Example 1(Succinyl/oxycarbonyl)methyl carbamic acid tert-butyl ester

To a 5° C solution of 8.76 g of N-(tert-butoxycarbonyl)glycine and 5.75 g of N-hydroxysuccinimide in 100 ml of dioxane and 160 ml of 1,2-dimethoxyethane is added 10.3 g of dicyclohexylcarbodiimide. The mixture is kept at 0° C for 24 hours. The reaction mixture is filtered, washed with dioxane and the filtrate concentrated in vacuo until a solid results. The solid is triturated with diethyl ether, collected and dried to give 12 g of the desired intermediate.

The above experimental is a literature procedure found in JACS Vol 66 1839(1939).

Comparative Example 2[7S-(7 α ,10 α)-2-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester

A mixture of 0.850 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline, 0.680 g sodium acetate in 25 ml of tetrahydrofuran and 5 ml of water is stirred at 25° C for 5 minutes. The solution is treated with 0.359 g of product from Example 1, stirred for 2 hours and extracted with chloroform. The organic layer is concentrated in vacuo to give 0.50 g of the desired product.

MS(FAB): m/z 630 (M+H).

Comparative Example 3[4S-(4 α ,12 α)]-9-[(Aminoacetyl)amino]-4,7-bis-dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate)

A solution of 0.030 g of product from Example 2 and 1.0 ml of trifluoroacetic acid is maintained at room temperature for 24 hours followed by concentrating in vacuo. The residue is triturated with methyl alcohol and the solid collected to give 0.024 g of the desired product. MS(FAB): m/z 530 (M+H).

Example 4Dimethylaminoacetyl chloride hydrochloride

A mixture of 15 g of N,N-dimethylglycine hydrochloride (pulverized and dried in a vacuum oven at 45-50° C for 24 hours) and 13.85 ml of thionyl chloride is heated, very slowly, in a sand bath to 78° C and kept at this temperature for 1 1/2 hours. Toluene is added to the mixture and the excess liquid is removed by pipette. This step is repeated several times. The solid is then transferred to a Buchner funnel, washed with methylene chloride and dried under vacuum at 50° C for 24 hours to yield 14.2 g of the desired intermediate.

Example 5[4S-(4 α ,12 α)]-4,7-Bis(dimethylamino)-9-[[dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a mixture of 6.68 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline disulfate in 120 ml of DMPU and acetonitrile is added 6.57 g of sodium carbonate. The mixture is stirred for 5 minutes, followed by the addition of 2.83 g of product from Example 4. The reaction is stirred for 1 hour, filtered and the filtrate is added slowly to a mixture of methylene chloride/ diethyl ether (1200ml/400ml). The solid is collected, dissolved in 250 ml methyl alcohol and added slowly to 1600 ml of methylene chloride. The precipitate is collected, washed with diethyl ether and dried to give 5.75 g of the desired product.

MS(FAB) : m/z 558 (M+H).

Example 6

[4S-(4 α ,12 α)]-9-[(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a room temperature solution of 0.334 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline disulfate, 6 ml of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, hereinafter called DMPU, and 2 ml of acetonitrile is added 0.318 g of sodium carbonate. The mixture is stirred for 5 minutes followed by the addition of 0.068 g of chloroacetyl chloride. The reaction is stirred for 30 minutes, filtered, and the filtrate added dropwise to 100 ml of diethyl ether, containing 1 ml of 1M hydrochloric acid in diethyl ether. The resulting solid is collected and dried to give 0.340 g of the desired intermediate.
MS(FAB): m/z 549 (M+H).

Example 6A

[4S-(4 α ,12 α)]-9-[(Chloroacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base)

The title compound is prepared by the procedure of Example 6, using 0.51 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride, 50 ml of DMPU, 5 ml of acetonitrile, 0.668 g of sodium carbonate and 0.452 g of chloroacetyl chloride to give 0.52 g of the desired product as the free base.
¹H NMR(DMSO-d₆): δ 9.3(s,1H); 7.9(s,1H); 4.45(s,2H).

Example 7

[4S-(4 α ,12 α)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrobromide

To a solution of 5.01 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline disulfate, 100 ml of DMPU and 25 ml of acetonitrile is added 5.0 g of sodium carbonate. The reaction is stirred, under argon, at room temperature for 5 minutes, followed by the addition of 3.03 g of bromoacetyl bromide. The stirring is continued for an additional hour. The solid is collected and the filtrate is added slowly to isopropyl alcohol/diethyl ether (200 ml/750ml). The yellow solid is collected, washed with isopropanol and diethyl ether to give 5.77 g of the desired intermediate.
MS(FAB): 593 (M+H).

Example 7A

[4S-(4 α ,12 α)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (free base)

To 0.20 g of product from Example 7 in 3 ml of 1,3-dimethyl-2-imidazolidinone is added 0.30 g of sodium bicarbonate. The reaction is stirred at room temperature for 15 minutes and filtered. The filtrate is added to 15 ml of diethyl ether and the resulting precipitate is collected to give 0.150 g of the desired intermediate as the free base.
MS(FAB): m/z 593 (M+H).

Example 8

[4S-(4 α ,12 α)]-9-[(Bromoacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

The title compound is prepared by the procedure of Example 6, using 0.668 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline disulfate, 6 ml of DMPU, 2 ml of acetonitrile, 0.636 g of sodium carbonate and 0.215 g of bromoacetyl chloride. Seven tenths of a gram of the desired intermediate is obtained.
MS(FAB): m/z 593 (M+H).

Example 9

[4S-(4 α ,12 α)]-9-[(2-Bromo-1-oxopropyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

The title compound is prepared by the procedure of Example 6 using 1.00 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline disulfate, 1.0 g of sodium carbonate and 0.648 g of 2-bromopropionyl bromide to give 0.981 g of the desired intermediate.
MS(FAB): m/z 607 (M+H).

Example 10

[4S-(4 α ,12 α)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

The title compound is prepared by the procedure of Example 6 using 1.34 g of 9-amino-4,7-bis(dimethylamino)-6-demethyl-6-deoxytetracycline disulfate, 1.3 g of sodium carbonate, 24 ml of DMPU, 8 ml of acetonitrile and 0.399 g of 4-bromobutyl chloride to give 1.45 g of the desired product.

Example 11

[4S-(4 α ,12 α)]-4,7-Bis(dimethylamino)-9-[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a solution of 0.15 g of product from Example 6 in 4 ml of DMPU is added 0.85 g of dimethylamine (40% in water). The reaction is stirred for 20 minutes followed by concentration in vacuo to remove excess dimethylamine. The mixture is filtered and the filtrate added, dropwise, to 70 ml of isopropyl alcohol/diethyl ether (1:1). To this solution is added 1 ml of 1M hydrochloric acid/diethyl ether. The resulting precipitate is collected, washed with isopropyl alcohol and diethyl ether, and dried to give 0.11 g of the desired product.

MS(FAB): m/z 558 (M+H).

Example 12

[4S-(4 α ,12 α)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

A mixture of 0.1258 g of product from Example 7, 5 ml of 40% methylamine in water and 5 ml of methyl alcohol, under Argon, is stirred at room temperature for 30 minutes. The excess methylamine is removed in vacuo and the residue diluted with a small volume of methyl alcohol. The diluted reaction solution is added dropwise to 100 ml of diethyl ether containing 1 ml of 1M hydrochloric acid in diethyl ether and 10 ml of isopropyl alcohol. The resulting solid is collected and dried to give 0.106 g of the desired product.

MS(FAB): m/z 544 (M+H).

Substantially following the methods described in detail herein above in Example 12, the compounds of this invention listed below in Examples 13-33 are prepared.

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
13	[7S-(7alpha,10aalpha)]-N-[9-(Amino-carbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,-10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-morpholineacetamide dihydrochloride	7	Morpholine	0.5 hr.	600(M+H)
14	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethyl-amino)-9-[[(ethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,-12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	7	Ethylamine (70% in water)	2 hr.	558(M+H)
15	[4S-(4alpha,12aalpha)]-9-[[(Cyclopropylamino)acetyl]amino]-4,7-bis(dimethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	7	Cyclopropyl-amine	2 hr.	570(M+H)
16	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethyl-amino)-9-[[(butylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	7	Butylamine	2 hr.	586(M+H)
17	[4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a-5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	7	Diethylamine	2 hr.	586(M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
18	[7S-(7alpha,10aalpha)]-N-[9-(Amino-carbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide dihydrochloride	7	Pyrrolidine	0.5 hr.	584 (M+H)
19	[7S-(7alpha,10aalpha)]-N-[9-(Amino-carbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-piperidineacetamide dihydrochloride	7	Piperidine	1 hr.	598 (M+H)
20	[7S-(7alpha,10aalpha)]-N-[9-(Amino-carbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-azetidineacetamide	7	Azetidine	0.5 hr.	570 (M+H)
21	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[[(propylamino)acetyl]amino]-2-naphthacene-carboxamide dihydrochloride	7	Propylamine	0.75 hr.	572 (M+H)
22	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethyl-amino)-9-[[[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide dihydrochloride	7	N-Hexylamine	2 hr.	614 (M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
23	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	9	Dimethylamine (40% in water)	2.5 hr.	572 (M+H)
24	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[2-(methylamino)-1-oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	9	Methylamine (40% in water)	2 hr.	558 (M+H)
25	[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidineacetamide dihydrochloride	9	Pyrrolidine	1 hr.	598 (M+H)
26	[4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(pentylamino) acetyl]amino]-2-naphthacenecarboxamide dihydrochloride	7	Amylamine	2 hr.	600 (M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
27	[4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[[(2-methylpropyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	7	Isobutylamine	2 hr.	586 (M+H)
28	[7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1H-imidazole-1-acetamide dihydrochloride	7	Imidazole	1 hr.	581 (M+H)
29	[4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-9-[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide disulfate	7	Dimethylamine	0.5 hr.	558 (M+H)
30	[4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-9-[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide	7	Dimethylamine	0.5 hr.	558 (M+H)

Example #	Name	Starting Material Prod. of Exp.	Reactant	Rx Time	MS(FAB): m/z
31	[4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[[4-(dimethylamino)-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	10	Dimethylamine (40% in water)	2 hr.	586 (M+H)
32	[4S-(4alpha,12aalpha)]-9-[[[Butylmethylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride	7	N-Methylbutylamine	2 hr.	600 (M+H)
33	[4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[[phenylmethylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride	7	Benzylamine	1 hr.	620 (M+H)

Example 34

[7S-(7 α , 10 $\alpha\alpha$)]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,7,10a,12-octahydro-1,8, 10a, 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]glycine phenylmethyl ester

To 0.30 g of benzylglycine hydrochloride in 3 ml of 1,3-dimethyl-2-imidazolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred at room temperature for 15 minutes and filtered. To the filtrate is added 0.20 g of product from Example 7A. The reaction mixture is stirred at room temperature for 1 hour and then added to diethyl ether. The resulting solid is collected.

Example 43


[7S-(7 α , 10 $\alpha\alpha$)]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,7,10a,12-octahydro-1,8, 10a, 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]glycine

One-tenth of a gram of product from Example 34 in 10 ml of 2-methoxyethane is reduced catalytically, in a Parr shaker, with 0.10 g of 10% palladium on carbon, at 30 psi of hydrogen, for 2 hours. The reaction mixture is filtered and the filtrate concentrated to give 0.050 g of the desired product.

FAB-MS: m/z 588 (M+H).

Claims

1. A process for producing 7-(substituted)-9-[(substituted glycy)amino]-6-demethyl-6-deoxytetracyclines of the formula:



I

wherein:

X is selected from amino, -NR¹R², or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = -NR¹R² and R¹ = hydrogen,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R¹ = methyl or ethyl,

R² = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R¹ = n-propyl,

R² = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R¹ = 1-methylethyl,

R² = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R¹ = n-butyl,

R² = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R¹ = 1-methylpropyl,

R² = 2-methylpropyl;


R is selected from R⁴(CH₂)_nCO-, n = 0-4,

and when n = 0,

R⁴ is selected from α -aminomethyl, α -aminoethyl, α -aminobutyl, α -amino-isobutyl and the enantiomers of said group; and when n = 1-4,

R⁴ is selected from amino, methylamino, ethylamino, n-propylamino, 1-methylethylamino, n-butylamino, 1-methylpropylamino, 2-methylpropylamino, 1,1-dimethylethylamino, n-pentylamino, 2-methylbutylamino, 1,1-dimethylpropylamino, 2,2-dimethylpropylamino, 3-methylbutylamino, n-hexylamino, 1-methylpentylamino, 1,1-dimethylbutylamino, 2,2-dimethylbutylamino, 3-methylpentylamino, 1,2-dimethylbutylamino, 1,3-dimethylbutylamino and 1-methyl-2-ethylpropylamino, cyclopropylamino, cyclobutylamino, benzylamino and phenylamino, dimethylamino, diethylamino, methyl(butyl)amino, ethyl(1-methylethyl)amino, monomethylbenzylamino, aziridinyl, azetidyl, pyrrolidinyl, 2-methylpyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) and 4-(1,2,4-triazolyl), aminoacetic acid, α -amino)propionic acid and the enantiomers of said group which comprises:

(a) mixing 9-amino-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof with a polar-aprotic solvent, an inert solvent, a base and reacting with a straight or branched haloacyl halide of the formula:



wherein:

Q is a halogen [selected from bromine, chlorine, fluorine or iodine];

and when n = 0,

Y is straight or branched α -halo(C₁-C₄)alkyl group selected from bromomethyl, chloromethyl, iodomethyl,

α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl;

and when n = 1-4,

Y is a halogen selected from bromine, chlorine, iodine and fluorine; O-toluenesulfonate; O-methylsulfonate or trifluoromethylsulfonate;

for 0.5 to 5 hours at from room temperature to the reflux temperature of the reaction and recovering 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof; and

(b) in the case of n = 1-4, reacting the 9-[(haloacyl, o-toluenesulphonylacyl, o-methylsulphonylacyl or o-trifluoromethylsulphonylacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof, in a polar-aprotic solvent, under an inert atmosphere of helium, nitrogen or argon, with a nucleophile having the formula, R⁴H, wherein R⁴ is hereinabove defined or in the case of n = 0 the 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracycline under the same conditions with ammonia; for from 0.5 to 2 hours at from room temperature to the reflux temperature of the reaction and isolating the compound of formula I or the pharmacologically acceptable organic and inorganic salt thereof.

2. The process of Claim 1 wherein:

X is selected from amino, -NR¹R², or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = -NR¹R²,

and when R¹ = methyl or ethyl,

R² = methyl or ethyl,

R is selected from R⁴(CH₂)_nCO-, n = 0-4,

and when n = 0,


R⁴ is selected from α -aminomethyl, α -aminoethyl, α -aminobutyl and the enantiomers of said group;

and when n = 1-4,

R⁴ is selected from amino, methylamino, ethylamino, n-propylamino, 1-methylethylamino, n-butylamino, n-pentylamino and n-hexylamino, cyclopropylamino and benzylamino, dimethylamino, diethylamino, methyl(butyl)amino, azetidyl, pyrrolidinyl, piperidinyl, morpholinyl and imidazolyl; and the pharmacologically ac-


ceptable organic and inorganic salts

3. A process for producing 7-(substituted)-9-[(substituted glycol)amino]-6-demethyl-6-deoxytetracyclines of the formula:




I

wherein X is dimethylamino and R is selected from:



which comprises:

- (a) mixing 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof with a polar-aprotic solvent, an inert solvent, a base and reacting with 2-bromo-propionyl bromide for 0.5 to 5 hours at from room temperature to the reflux temperature of the reaction and recovering 9-[(2-bromo-1-oxopropyl)-amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof; and
 - (b) reacting the 9-[(2-bromo-1-oxopropyl)-amino]-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof, in a polar-aprotic solvent, under an inert atmosphere of helium, nitrogen or argon, with dimethylamine or methylamine: for from 0.5 to 2 hours at from room temperature to the reflux temperature of the reaction and isolating the product or the pharmacologically acceptable organic and inorganic salt thereof.
4. The process for producing novel straight or branched 9-[(haloacyl)amino]-7-(substituted)-6-demethyl-6-deoxytetracyclines of the formula:



II

wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = $-NR^1R^2$ and R^1 = hydrogen,

R^2 = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R^1 = methyl or ethyl,

R^2 = methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl,

and when R^1 = n-propyl,

R^2 = n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R^1 = 1-methylethyl,

R^2 = n-butyl, 1-methylpropyl or 2-methylpropyl,

and when R^1 = n-butyl,

R^2 = n-butyl, 1-methylpropyl or 2-methylpropyl;

and when R^1 = 1-methylpropyl,

R^2 = 2-methylpropyl;


and when n = 0,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl;

and when n = 1-4,

Y is halogen selected from bromine, chlorine, iodine and fluorine; O-toluenesulfonate; O-methylsulfonate or trifluoromethylsulfonate; which comprises

(a) mixing 9-amino-7-(substituted)-6-demethyl-6-deoxytetracycline or the pharmacologically acceptable organic and inorganic salt thereof with a polar-aprotic solvent, an inert solvent, a base and reacting with a straight or branched haloacyl halide of the formula:



wherein Y, n and Q are hereinabove defined;

for 0.5 to 5 hours at from room temperature to the reflux temperature of the reaction and isolating the compound of formula II or the pharmacologically acceptable organic and inorganic salt thereof.

5. The process of Claim 4 wherein:

X is selected from amino, $-NR^1R^2$, or halogen; the halogen is selected from bromine, chlorine, fluorine and iodine; and when X = $-NR^1R^2$,

and when R^1 = methyl or ethyl,

R^2 = methyl, ethyl,

and when n = 0,

Y is straight or branched α -halo(C_1 - C_4)alkyl group selected from bromomethyl, chloromethyl, iodomethyl, α -bromoethyl, α -chloroethyl, α -bromobutyl and α -chloro-isobutyl;

and when n = 1-4,

Y is halogen selected from bromine, chlorine, iodine and fluorine, O-toluenesulfonate, O-methylsulfonate or trifluoromethylsulfonate; and the pharmacologically acceptable organic and inorganic salt.


6. The process of any one of Claims 1 to 5 wherein said polar-aprotic solvent is selected from 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoramide, dimethylformamide, dimethylacetamide, N-methylpyrrolidone, 1,2-dimethoxyethane, tetrahydrofuran, water, methanol and equivalent thereof.

7. The process of any one of Claims 1 to 5 wherein said inert solvent is selected from acetonitrile, methylene chloride, tetrahydrofuran, chloroform, carbon tetrachloride, 1,2-dichloroethane, tetrachloroethane, diethyl ether, t-butyl methyl ether, isopropyl ether and equivalent thereof.

8. The process of any one of Claims 1 to 5 wherein said base is selected from sodium carbonate, sodium bicarbonate, sodium acetate, potassium carbonate, potassium bicarbonate, triethylamine, cesium carbonate, lithium carbonate and equivalent thereof.


Patentansprüche

1. Verfahren zur Herstellung von 7-(substituiert)-9-[(substituiertes Glycyl)amino]-6-demethyl-6-desoxytetracyclinen der Formel:



worin X aus Amino, -NR¹R² oder Halogen ausgewählt ist; das Halogen aus Brom, Chlor, Fluor und Iod ausgewählt ist; und wenn X = -NR¹R² ist und R¹ = Wasserstoff ist, R² = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl ist; und wenn R¹ = Methyl oder Ethyl ist, R² = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = n-Propyl ist, R² = n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = 1-Methylethyl ist, R² = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = n-Butyl, R² = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = 1-Methylpropyl ist, R² = 2-Methylpropyl ist; R aus R⁴(CH₂)_nCO- ausgewählt ist, n = 0-4 ist, und wenn n = 0 ist, R⁴ aus α-Aminomethyl, α-Aminoethyl, α-Aminobutyl, α-Amino-isobutyl und den Enantiomeren dieser Gruppe ausgewählt ist; und wenn n = 1-4 ist, R⁴ aus Amino, Methylamino, Ethylamino, n-Propylamino, 1-Methylethylamino, n-Butylamino, 1-Methylpropylamino, 2-Methylpropylamino, 1,1-Dimethylethylamino, n-Pentylamino, 2-Methylbutylamino, 1,1-Dimethylpropylamino, 2,2-Dimethylpropylamino, 3-Methylbutylamino, n-Hexylamino, 1-Methylpentylamino, 1,1-Dimethylbutylamino, 2,2-Dimethylbutylamino, 3-Methylpentylamino, 1,2-Dimethylbutylamino, 1,3-Dimethylbutylamino und 1-Methyl-2-ethylpropylamino, Cyclopropylamino, Cyclobutylamino, Benzylamino und Phenylamino, Dimethylamino, Diethylamino, Methyl(butyl)amino, Ethyl(1-methylethyl)amino, Monomethylbenzylamino, Aziridinyl, Azetidiny, Pyrrolidinyl, 2-Methylpyrrolidinyl, Piperidinyl, Morpholinyl, Imidazolyl, 1-Pyrrolyl, 1-(1,2,3-Triazolyl) und 4-(1,2,4-Triazolyl), Aminoessigsäure, α-Aminopropionsäure und den Enantiomeren dieser Gruppe ausgewählt ist, welches umfaßt:


(a) Mischen von 9-Amino-7-(substituiert)-6-demethyl-6-desoxytetracyclin oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon mit einem polar-aprotischen Lösungsmittel, einem inerten Lösungsmittel, einer Base, und Umsetzen mit einem geraden oder verzweigten Haloacylhalid der Formel:



worin Q ein Halogen ist [ausgewählt aus Brom, Chlor, Fluor oder Iod]; und wenn n = 0 ist, Y gerade oder verzweigte α-Halo(C₁-C₄-)alkylgruppe ist, ausgewählt aus Brommethyl, Chlormethyl, Iodmethyl, α-Bromethyl, α-Chlorethyl, α-Brombutyl und α-Chlorisobutyl; und wenn n = 1-4 ist, Y ein Halogen ist, ausgewählt aus Brom, Chlor, Iod und Fluor; O-Toluolsulfonat; O-Methylsulfonat oder Trifluormethylsulfonat; während 0,5 bis 5 Stunden bei Zimmertemperatur bis zur Rückflußtemperatur der Reaktion, und Rückgewinnung von 9-[(Haloacyl)amino]-7-(substituiert)-6-demethyl-6-desoxytetracyclin oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon; und

(b) wenn $n = 1-4$ ist, Umsetzung des 9-[(Haloacyl)-o-Toluolsulfonylacyl]-o-Methylsulfonylacyl oder o-Trifluor-methylsulfonylacyl)-amino]-7-(substituiert)-6-demethyl-6-desoxytetracyclins oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon in einem polaraprotischen Lösungsmittel unter einer inerten Atmosphäre von Helium, Stickstoff oder Argon mit einem Nukleophilen der Formel R^4H , worin R^4 oben definiert ist oder, wenn $n = 0$ ist, des 9-[(Haloacyl)amino]-7-(substituiert)-6-demethyl-6-desoxytetracyclins unter den gleichen Bedingungen mit Ammoniak; während 0,5 bis 2 Stunden bei Zimmertemperatur bis zur Rückflußtemperatur der Reaktion und Isolieren der Verbindung der Formel I oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon.

2. Verfahren gemäß Anspruch 1, worin X aus Amino, $-NR^1R^2$ oder Halogen ausgewählt ist; das Halogen aus Brom, Chlor, Fluor und Iod ausgewählt ist; und wenn $X = -NR^1R^2$ ist, und wenn $R^1 =$ Methyl oder Ethyl ist, $R^2 =$ Methyl oder Ethyl ist, R aus $R^4(CH_2)_nCO-$ ausgewählt ist, $n = 0-4$ ist und wenn $n = 0$ ist, R^4 aus α -Aminomethyl, α -Aminoethyl, α -Aminobutyl und den Enantiomeren dieser Gruppe ausgewählt ist; und wenn $n = 1-4$ ist, R^4 ausgewählt ist aus Amino, Methylamino, Ethylamino, n-Propylamino, 1-Methylethylamino, n-Butylamino, n-Pentylamino und n-Hexylamino, Cyclopropylamino und Benzylamino, Dimethylamino, Diethylamino, Methyl(butyl)amino, Azetidiny, Pyrrolidiny, Piperidiny, Morpholiny und Imidazolyl; und die pharmakologisch annehmbaren organischen und anorganischen Salze.
3. Verfahren zur Herstellung von 7-(substituiert)-9-[(substituiertes Glycyl)amino]-6-demethyl-6-desoxytetracyclinen der Formel




worin X Dimethylamino ist und R aus




ausgewählt ist, welches umfaßt:

- (a) Mischen von 9-Amino-7-(dimethylamino)-6-demethyl-6-desoxytetracyclin oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon mit einem polar-aprotischen Lösungsmittel, einem inerten Lösungsmittel, einer Base, und Umsetzen mit 2-Brompropionylbromid während 0,5 bis 5 Stunden bei Zimmertemperatur bis zur Rückflußtemperatur der Reaktion und Rückgewinnung von 9-[(2-Brom-1-oxopropyl)amino]-7-(substituiert)-6-demethyl-6-desoxytetracyclin oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon; und
- (b) Umsetzen des 9-[(2-Brom-1-oxopropyl)amino]-7-(substituiert)-6-demethyl-6-desoxytetracyclins oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon in einem polar-aprotischen Lösungsmittel unter einer inerten Atmosphäre von Helium, Stickstoff oder Argon mit Dimethylamin oder Methylamin; während 0,5 bis 2 Stunden bei Zimmertemperatur bis zur Rückflußtemperatur der Reaktion und Isolieren des Produktes oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon.
4. Verfahren zur Herstellung neuartiger gerader oder verzweigter 9-[(Haloacyl)amino]-7-(substituiert)-6-demethyl-6-desoxytetracyclino der Formel:



15 worin X aus Amino, -NR¹R² oder Halogen ausgewählt ist; das Halogen aus Brom, Chlor, Fluor und Iod ausgewählt ist; und wenn X = -NR¹R² ist und R¹ = Wasserstoff ist, R² = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl, 2-Methylpropyl oder 1,1-Dimethylethyl ist; und wenn R¹ = Methyl oder Ethyl ist, R² = Methyl, Ethyl, n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = n-Propyl ist, R² = n-Propyl, 1-Methylethyl, n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = 1-Methylethyl ist, R² = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = n-Butyl ist, R² = n-Butyl, 1-Methylpropyl oder 2-Methylpropyl ist; und wenn R¹ = 1-Methylpropyl ist, R² = 2-Methylpropyl ist; und wenn n = 0 ist, Y gerade oder verzweigte α-Halo(C₁-C₄)alkylgruppe ist, ausgewählt aus Brommethyl, Chlormethyl, Iodmethyl, α-Bromethyl, α-Chlorethyl, α-Brombutyl und α-Chlorisobutyl; und wenn n = 1-4 ist, Y Halogen ist, ausgewählt aus Brom, Chlor, Iod und Fluor; O-Toluolsulfonat, O-Methylsulfonat oder Trifluormethylsulfonat; welches umfaßt:

25 (a) Mischen von 9-Amino-7-(substituiert)-6-demethyl-6-desoxytetracyclin oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon mit einem polar-aprotischen Lösungsmittel, einem inerten Lösungsmittel, einer Base, und Umsetzen mit einem geraden oder verzweigten Haloacylhalid der Formel:




worin Y, n und Q oben definiert sind; während 0,5 bis 5 Stunden bei Zimmertemperatur bis zur Rückflußtemperatur der Reaktion, und Isolieren der Verbindung der Formel II oder des pharmakologisch annehmbaren organischen und anorganischen Salzes davon.

- 40 5. Verfahren gemäß Anspruch 4, worin X aus Amino, -NR¹R² oder Halogen ausgewählt ist; das Halogen aus Brom, Chlor, Fluor und Iod ausgewählt ist; und wenn X = -NR¹R² ist, und wenn R¹ = Methyl oder Ethyl ist, R² = Methyl, Ethyl ist, und wenn n = 0 ist, Y gerade oder verzweigte α-Halo(C₁-C₄)alkylgruppe ist, ausgewählt aus Brommethyl, Chlormethyl, Iodmethyl, α-Bromethyl, α-Chlorethyl, α-Brombutyl und α-Chlorisobutyl; und wenn n = 1-4 ist, Y Halogen ist, ausgewählt aus Brom, Chlor, Iod und Fluor, O-Toluolsulfonat, O-Methylsulfonat oder Trifluormethylsulfonat; und das pharmakologisch annehmbare organische und anorganische Salz.
- 45 6. Verfahren gemäß einem der Ansprüche 1 bis 5, worin das polar-aprotische Lösungsmittel aus 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidon, 1,3-Dimethyl-2-imidazolidinon, Hexamethylphosphoramid, Dimethylformamid, Dimethylacetamid, N-Methylpyrrolidon, 1,2-Dimethoxyethan, Tetrahydrofuran, Wasser, Methanol deren und Äquivalent ausgewählt ist.
- 50 7. Verfahren gemäß einem der Ansprüche 1 bis 5, worin das inerte Lösungsmittel aus Acetonitril, Methylenechlorid, Tetrahydrofuran, Chloroform, Tetrachlorkohlenstoff, 1,2-Dichlorethan, Tetrachlorethan, Diethylether, t-Butylmethylether, Isopropylether und deren Äquivalent ausgewählt ist.
- 55 8. Verfahren gemäß einem der Ansprüche 1 bis 5, worin die Base aus Natriumcarbonat, Natriumbicarbonat, Natriumacetat, Kaliumcarbonat, Kaliumbicarbonat, Triethylamin, Cäsiumcarbonat, Lithiumcarbonat und deren Äquivalent ausgewählt ist.

Revendications

1. Procédé de production de 7-(substituée)-8-[(substitué glycy)lamino]-6-déméthyl-6-déoxytétracyclines de formule I :



dans laquelle :

X est choisi parmi amino, -NR¹R², ou halogène; l'halogène est choisi parmi le brome, le chlore, le fluor et l'iode, et quand X = -NR¹R² et R¹ = hydrogène,

R² = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyléthyle;

et quand R¹ = méthyle ou éthyle,

R² = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R¹ = n-propyle,

R² = n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R¹ = 1-méthyléthyle,

R² = n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R¹ = n-butyle,

R² = n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R¹ = 1-méthylpropyle,

R² = 2-méthylpropyle;

R est choisi parmi R⁴(CH₂)_nCO-, n = 0-4,


et quand n = 0,

R⁴ est choisi parmi α-aminométhyle, α-aminoéthyle, α-aminobutyle, aminoisobutyle, et les énantiomères dudit radical;

et quand n = 1-4,

R⁴ est choisi parmi amino, méthylamino, éthylamino, n-propylamino, l-méthyléthylamino, n-butylamino, 1-méthylpropylamino, 2-méthylpropylamino, 1,1-diméthyléthylamino, n-pentylamino, 2-méthylbutylamino, 1,1-diméthylpropylamino, 2,2-diméthylpropylamino, 3-méthylbutylamino, n-hexylamino, 1-méthylpentylamino, l,l-diméthylbutylamino, 2,2-diméthylbutylamino, 3-méthylpentylamino, 1,2-diméthylbutylamino, 1,3-diméthylbutylamino et l-méthyl-2-éthylpropylamino, cyclopropylamino, cyclobutylamino, benzylamino et phénylamino, diméthylamino, diéthylamino, méthyl(butyl)amino, éthyl(1-méthyléthyl)amino, monométhylbenzylamino, aziridinyle, azétidinyle, pyrrolidinyle, 2-méthylpyrrolidinyle, pipéridinyle, morpholinyle, imidazolyle, 1-pyrrolyle, 1-(1,2,3-triazolyle) et 4-(1,2,4-triazolyle), acide aminoacétique, acide α-aminopropionique et les énantiomères dudit radical qui comprend :

(a) le mélange de la 9-amino-7-(substituée)-6-déméthyl-6-déoxytétracycline ou d'un sel organique et inorganique pharmacologiquement acceptable de celle-ci avec un solvant polaire, exempt de proton, dans un solvant inerte, une base et la réaction avec un halogénure d'haloacyle à chaîne droite ou ramifiée de formule :



dans laquelle,

Q est un halogène (choisi parmi le brome, le chlore, le fluor et l'iode),
et quand $n = 0$,

Y est un radical α -halo(alcoyle en C_1 - C_4 à chaîne droite ou ramifiée choisi parmi bromométhyle, chlorométhyle, iodométhyle, α -bromoéthyle, α -chloroéthyle, α -bromobutyle, et α -chloroisobutyle;
et quand $n = 1-4$,

Y est un halogène choisi parmi le brome, le chlore, l'iode et le fluor; o-toluènesulfonate; o-méthylsulfonate ou trifluorométhylsulfonate;

pendant 0,5 à 5 heures à une température allant de la température ambiante à la température de reflux de la réaction et en récupérant la 9-[(haloacyl)amino]-7-(substituée)-6-déméthyl-6-déoxytétracycline ou le sel organique et inorganique pharmacologiquement acceptable de celle-ci; et

(b) dans le cas où $n = 1-4$, la réaction de la 9-[(haloacyl, o-toluènesulfonylacyle, o-méthylsulfonylacyle, ou trifluorométhylsulfonylacyle)amino]-7-(substituée)-6-déméthyl-6-déoxytétracycline ou le sel organique et inorganique pharmacologiquement acceptable de celle-ci, dans un solvant polaire, exempt de proton, sous une atmosphère inerte d'hélium, d'azote ou d'argon, avec un nucléophile ayant la formule R^4H , dans laquelle R^4 est défini ci-dessus, ou dans le cas de $n = 0$, la 9-[(haloacyl)amino]-7-(substituée)-6-déméthyl-6-déoxytétracycline sous les mêmes conditions avec de l'ammoniac; pendant 0,5 à 2 heures à une température allant de la température ambiante à la température de reflux de la réaction et en isolant le composé de formule I ou le sel organique et inorganique pharmacologiquement acceptable de celui-ci.

2. Procédé selon la revendication 1, dans lequel.

X est choisi parmi amino, $-\text{NR}^1\text{R}^2$, ou halogène; l'halogène est choisi parmi le brome, le chlore, le fluor et l'iode; et quand $\text{X} = -\text{NR}^1\text{R}^2$,

et $\text{R}^1 =$ méthyle ou éthyle,

$\text{R}^2 =$ méthyle ou éthyle,


R est choisi parmi $\text{R}^4(\text{CH}_2)_n\text{CO}-$, $n = 0-4$,

et quand $n = 0$,


R^4 est choisi parmi α -aminométhyle, α -aminoéthyle, α -aminobutyle et les énantiomères dudit radical; et quand $n = 1-4$,

R^4 est choisi parmi amino, méthylamino, éthylamino, n-propylamino, 1-méthyléthylamino, n-butylamino, n-pentylamino et n-hexylamino, cyclopropylamino et benzylamino, diméthylamino, diéthylamino, méthyl(butyl)amino, azétidinyle, pyrrolidinyle, pipéridinyle, morpholinyle et imidazolyle; et les sels organiques et inorganiques pharmacologiquement acceptables de ceux-ci.

3. Procédé de production de 7-(substituées)-9-[(substitué glycy)amino]-6-déméthyl-6-déoxytétracyclines de formule :




dans laquelle X est diméthylamino et R est choisi parmi :



qui comprend :

- (a) le mélange de 9-amino-7-(diméthylamino)-6-déméthyl-6-déoxytétracycline ou du sel organique et inorganique pharmacologiquement acceptable de celle-ci avec un solvant polaire exempt de proton, un solvant inerte, une base et la réaction avec du bromure de 2-bromopropionyle pendant 0,5 à 5 heures à une température allant de la température ambiante à la température de reflux de la réaction et en récupérant la 9-[(2-bromo-1-oxopropyl)amino]-7-(substituée)-6-déméthyl-6-déoxytétracycline ou le sel organique et inorganique pharmacologiquement acceptable de celle-ci; et
 - (b) la réaction de la 9-[(2-bromo-1-oxopropyl) amino]-7-(substituée)-6-déméthyl-6-déoxytétracycline ou du sel organique et inorganique pharmacologiquement acceptable de celle-ci, dans un solvant polaire, exempt de proton, sous une atmosphère inerte d'hélium, d'azote ou d'argon, avec de la diméthylamine ou de la méthylamine; pendant 0,5 à 2 heures à une température allant de la température ambiante à la température de reflux de la réaction et en isolant le produit ou le sel organique et inorganique pharmacologiquement acceptable de celui-ci.
4. Procédé de production de nouveaux composés à chaîne droite ou ramifiée de 9-[(haloacyl)amino]-7-(substituées)-6-déméthyl-6-déoxytétracyclines de formule :



dans laquelle :

X est choisi parmi amino, -NR¹R², ou halogène: l'halogène est choisi parmi le brome, le chlore, le fluor et l'iode; et quand X = -NR¹R² et R¹ = hydrogène, R² = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle, 2-méthylpropyle ou 1,1-diméthyl-

l'éthyle;

et quand R^1 = méthyle ou éthyle

R^2 = méthyle, éthyle, n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R^1 = n-propyle,

R^2 = n-propyle, 1-méthyléthyle, n-butyle, 1-méthylpropyle ou 2-méthylpropyle

et quand R^1 = 1-méthyléthyle,

R^2 = n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R^1 = n-butyle

R^2 = n-butyle, 1-méthylpropyle ou 2-méthylpropyle;

et quand R^1 = 1-méthylpropyle,

R^2 = 2-méthylpropyle;

et quand $n = 0$.


Y est un radical α -halo(alcoyle en C_1 - C_4) à chaîne droite ou ramifiée choisi parmi bromométhyle, chlorométhyle, iodométhyle, α -bromoéthyle, α -chloroéthyle, α -bromobutyle

et α -chloroisobutyle;

et quand $n = 1-4$,

Y est un halogène choisi parmi le brome, le chlore, l'iode et le fluor; o-toluènesulfonate; o-méthylsulfonate ou trifluorométhylsulfonate; qui comprend

(a) le mélange de 9-amino-7-(substituée)-6-déméthyl-6-déoxytétracycline ou du sel organique et inorganique pharmacologiquement acceptable de celle-ci avec un solvant polaire exempt de proton, un solvant inerte, une base et la réaction avec un halogénure d'haloacyle de formule :



dans laquelle Y, n et Q sont tels que définis ci-dessus, pendant 0.5 à 5 heures à une température allant de la température ambiante à la température de reflux de la réaction et l'isolement du composé de formule II ou du sel organique et inorganique pharmacologiquement acceptable de celui-ci.

5. Composé selon la revendication 4, dans lequel :

X est choisi parmi amino, $-NR^1R^2$, ou halogène; l'halogène est choisi parmi le brome, le chlore, le fluor et l'iode; et quand $X = -NR^1R^2$

et quand R^1 = méthyle ou éthyle,

R^2 = méthyle ou éthyle,

et quand $n = 0$,

Y est un radical α -halo(alcoyle en C_1 - C_4) à chaîne droite ou ramifiée choisi parmi bromométhyle, chlorométhyle, iodométhyle, α -bromoéthyle, α -chloroéthyle, α -bromobutyle et α -chloroisobutyle;

et quand $n = 1-4$,

Y est un halogène choisi parmi le brome, le chlore, l'iode et le fluor; o-toluènesulfonate; o-méthylsulfonate ou trifluorométhylsulfonate; et les sels organiques et inorganiques pharmacologiquement acceptables.

6. Procédé selon l'une quelconque des revendications 1 à 5 dans lequel ledit solvant polaire exempt de proton est choisi parmi la 1,3-diméthyl-3,4,5,6-tétrahydro-2(1H)-pyrimidone, la 1,3-diméthyl-2-imidazolidinone, l'hexaméthylphosphoramide, le diméthylformamide, le diméthylacétamido, la N-méthylpyrrolidone, le 1,2-diméthoxyéthane, le tétrahydrofuranne, l'eau, le méthanol et des équivalents de ceux-ci.

7. Procédé selon l'une quelconque des revendications 1 à 5 dans lequel ledit solvant inerte est choisi parmi l'acétonitrile, le chlorure de méthylène, le tétrahydrofuranne, le chloroforme, le tétrachlorure de carbone, le 1,2-dichloroéthane, le tétrachloroéthane, le diéthyléther, le t-butylméthyléther, l'isopropyléther et des équivalents de ceux-ci.

8. Procédé selon l'une quelconque des revendications 1 à 5 dans lequel ladite base est choisie parmi le carbonate

EP 0 582 790 B1

de sodium, le bicarbonate de sodium, l'acétate de sodium, le carbonate de potassium, le bicarbonate de potassium, la triéthylamine, le carbonate de césium, le carbonate de lithium et des équivalents de ceux-ci.

5

10

15

20

25

30

35

40

45

50

55